Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors


Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

Therapies based on GLP-1 receptor agonists and DPP-4 inhibitors have a series of benefits compared to conventional therapies for type 2 diabetes mellitus (DM2). Several new agents of this class of drugs have been approved in recent years and are now in clinical practice. In this transmission, Jaime Davidson, MD, presents an overview of recent developments with the use of incretin-based therapies for the treatment of DM2.

Earn CME / CE credit here –

Video credits to ProjectsInKnowledge YouTube channel





  • Your reaction?
    Angry Angry
    0
    Angry
    Lol Lol
    0
    Lol
    Love It! Love It!
    0
    Love It!
    Nice Nice
    0
    Nice
    Now I Know Now I Know
    0
    Now I Know
    Sad Sad
    0
    Sad
    Surprised Surprised
    0
    Surprised
    Wow! Wow!
    0
    Wow!
    WTF WTF
    0
    WTF

    Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

    log in

    reset password

    Back to
    log in